SCHEMBL14917445

SCHEMBL14917445

NC(=O)c1c(N)ccnc1-c1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.52
BMPR1B O00238 1/20 0.52
PIK3C2G O75747 1/20 0.52
CDKL5 O76039 1/20 0.52
TYK2 P29597 1/20 0.52
CLK2 P49760 1/20 0.52
DYRK1A Q13627 1/20 0.52
STK32B Q9NY57 1/20 0.52
PI4KB Q9UBF8 1/20 0.52
IRAK3 Q9Y616 1/20 0.52
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
HSP90AA1 P07900 6/20 0.45
MAP4K4 O95819 1/20 0.44
CSNK1G2 P78368 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
MAP4K5 Q9Y4K4 1/20 0.44
CYP2A6 P11509 1/20 0.43
CA12 O43570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14917447 0.79 HSP90AA1 (0.46) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL30108283 0.78 PARP1 (0.50) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL31032045 0.78 PARP1 (0.50) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL4936429 0.78 PARP1 (0.50) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL14917460 0.78 MEN1 (0.47) PIM1CLK4SRCIKBKB
SCHEMBL944311 0.75 PDGFRB (0.58) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL17610492 0.75 IKBKB (0.49) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL17610510 0.75 PIM1 (0.53) PIM1BMPR1BPIK3C2GCDKL5TYK2
SCHEMBL14917433 0.73 MKNK1 (0.50) PIM1HSP90AA1MKNK2CYP2A6IKBKB
SCHEMBL16246953 0.73 RIPK2 (0.71) SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3193611-B1 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2021-03-24 EP disclosed
EP-3193611-A2 MK2 INHIBITORS AND USES THEREOF CELGENE CAR LLC (BM) 2017-07-26 EP disclosed
WO-2016044463-A2 MK2 INHIBITORS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-03-24 WO disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK PIM1 1831/4885BMPR1B 4018/4885PIK3C2G 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.